VEGFC-156S treatment enhanced lymphangiogenesis without affecting hypercholesterolemia but did not improve lymphatic drainage, reduce plasma cholesterol, and atherosclerosis lesion size [86]. This evidence concerns the gene VEGFC and familial hypercholesterolemia.